Open Access
Open access
Journal of Personalized Medicine, volume 12, issue 6, pages 895

VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages

Sergey V Kulemzin 1
Maria V Sergeeva 2
Konstantin Baranov 1
Sergey V Guselnikov 1
Tatyana N Belovezhets 1
Olga Yu Volkova 1
Alexander M. Najakshin 1
Nikolai A Chikaev 1
Daria Danilenko 2
Publication typeJournal Article
Publication date2022-05-29
Q2
Q1
SJR0.736
CiteScore4.1
Impact factor3
ISSN20754426
PubMed ID:  35743680
Medicine (miscellaneous)
Abstract

Immune evasion of SARS-CoV-2 undermines current strategies tocounteract the pandemic, with the efficacy of therapeutic virus-neutralizing monoclonal antibodies (nAbs) being affected the most. In this work, we asked whether two previously identified human cross-neutralizing nAbs, iB14 (class VH1-58) and iB20 (class VH3-53/66), are capable of neutralizing the recently emerged Omicron (BA.1) variant. Both nAbs were found to bind the Omicron RBD with a nanomolar affinity, yet they displayed contrasting functional features. When tested against Omicron, the neutralizing activity of iB14 was reduced 50-fold, whereas iB20 displayed a surprising increase in activity. Thus, iB20 is a unique representative of the VH3-53/66-class of nAbs in terms of breadth of neutralization, which establishes it as a candidate for COVID-19 therapy and prophylactics.

Found 
Found 

Top-30

Journals

1
2
Vaccines
2 publications, 50%
Frontiers in Immunology
1 publication, 25%
Russian Chemical Reviews
1 publication, 25%
1
2

Publishers

1
2
MDPI
2 publications, 50%
Frontiers Media S.A.
1 publication, 25%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 25%
1
2
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Kulemzin S. V. et al. VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages // Journal of Personalized Medicine. 2022. Vol. 12. No. 6. p. 895.
GOST all authors (up to 50) Copy
Kulemzin S. V., Sergeeva M. V., Baranov K., Gorchakov A. A., Guselnikov S. V., Belovezhets T. N., Volkova O. Yu., Najakshin A. M., Chikaev N. A., Danilenko D., Taranin A. VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages // Journal of Personalized Medicine. 2022. Vol. 12. No. 6. p. 895.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.3390/jpm12060895
UR - https://doi.org/10.3390/jpm12060895
TI - VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages
T2 - Journal of Personalized Medicine
AU - Kulemzin, Sergey V
AU - Sergeeva, Maria V
AU - Baranov, Konstantin
AU - Gorchakov, Andrey A
AU - Guselnikov, Sergey V
AU - Belovezhets, Tatyana N
AU - Volkova, Olga Yu
AU - Najakshin, Alexander M.
AU - Chikaev, Nikolai A
AU - Danilenko, Daria
AU - Taranin, Alexander
PY - 2022
DA - 2022/05/29
PB - MDPI
SP - 895
IS - 6
VL - 12
PMID - 35743680
SN - 2075-4426
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2022_Kulemzin,
author = {Sergey V Kulemzin and Maria V Sergeeva and Konstantin Baranov and Andrey A Gorchakov and Sergey V Guselnikov and Tatyana N Belovezhets and Olga Yu Volkova and Alexander M. Najakshin and Nikolai A Chikaev and Daria Danilenko and Alexander Taranin},
title = {VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages},
journal = {Journal of Personalized Medicine},
year = {2022},
volume = {12},
publisher = {MDPI},
month = {may},
url = {https://doi.org/10.3390/jpm12060895},
number = {6},
pages = {895},
doi = {10.3390/jpm12060895}
}
MLA
Cite this
MLA Copy
Kulemzin, Sergey V., et al. “VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages.” Journal of Personalized Medicine, vol. 12, no. 6, May. 2022, p. 895. https://doi.org/10.3390/jpm12060895.
Found error?